Incyte announces FDA approval for Zynyz™
Congratulations to Incyte on their FDA approval for Zynyz™, a treatment for adults with metastatic...
read Details
The team at Acadia Pharmaceuticals Inc. announced FDA Approval on their drug Daybue, for the first approved treatment for Rett syndrome, a genetic brain disorder, making it the first approved drug for this condition.
Modality Solutions helped Acadia bring the drug to market by developing and executing the transport validation strategy for Daybue. You can read the full press release here.
Congratulations to Incyte on their FDA approval for Zynyz™, a treatment for adults with metastatic...
read DetailsCongratulations to Amicus Therapeutics for their European Commission approval for Pombiliti™ in patients with Late-Onset...
read DetailsThe team at Atara Biotherapeutics announced EU Approval on their allogeneic T-cell therapy to treat adult...
read Details